primary care medicines formulary - gp ref · primary care and so not all may be specifically...
TRANSCRIPT
Primary Care
Medicines
Formulary
June 2016
1
Scope of this formulary
The aim of this formulary is to promote safe, effective and affordable first choice prescribing, when initiated within a primary care setting within Bedfordshire Clinical Commissioning Group (BCCG). It does not cover specialist drugs initiated in secondary or tertiary care. Policies and shared care arrangements for these drugs can be found within the Joint Prescribing Committee (JPC) section of the BCCG website Recommendations are also included in the ScriptSwitch® profile where appropriate.
The formulary is not intended to supersede NICE Technology Appraisals (TAs). Not all NICE approved drugs are appropriate for general initiation in primary care and so not all may be specifically mentioned. Clinicians can and should prescribe medicines approved by NICE TAs where patients meet the clinical criteria set in the guidance and where it is the most appropriate treatment option in the clinical judgement of the treating clinician.
The process for amendments to this formulary is set out on the BCCG website. The current version of this formulary will be available on the BCCG website.
2
Before changing a medicine check patients’ adherence to their existing prescribed medication –
Can they take their medicines? Do they take their medicines?
BNF Section Preparations Comments
1: GASTRO-INTESTINAL SYSTEM
1.1 Dyspepsia and gastro-oesophageal reflux disease
1st choice Peptac® sugar free suspension aniseed/peppermint 500ml 2nd choice low sodium option Gaviscon® Advance sugar free suspension aniseed/peppermint 500ml
6.2mmol Na+/10ml. Dose 10-20ml. Pack size 500ml 4.6mmol Na+ 2mmol K+ / 10ml. Dose 5-10ml. Pack size 250ml or 500ml
1.2 Antispasmodics & other drugs altering gut motility
Hyoscine butylbromide tablets 10mg Mebeverine tablets 135mg Peppermint oil 0.2ml gastro resistant capsules
NB not modified release
1.3.1 H2-receptor antagonists Ranitidine tablets 150mg & 300mg
1.3.5 Proton pump inhibitors Lansoprazole gastro resistant capsules 15mg & 30mg Omeprazole gastro resistant capsules 10mg & 20mg Pantoprazole gastro resistant tablets 20mg & 40mg
1.4 Acute diarrhoea Loperamide capsules 2mg
1.5 Chronic bowel disorders Octasa® (mesalazine modified release) tablets 400mg & 800mg tablets Pentasa® (mesalazine modified release) tablets 500mg & 1000mg Salazopyrin EN® tablets (sulphasalazine enteric coated ) 500mg
3
BNF Section Preparations Comments
1.6.1 Bulk-forming laxatives Ispaghula husk 3.5g effervescent granules, gluten free, sugar free (Fybogel®)
Low Na+
1.6.2 Stimulant laxatives Senna tablets 7.5mg & sugar free oral solution 7.5mg/ 5ml
1.6.4 Osmotic laxatives Lactulose solution 500ml Cosmocol® lemon and lime sachets Cosmocol® orange sachets Cosmocol® plain sachets Cosmocol Half® 6.9g sachets Cosmocol Paediatric® 6.9g sachets
Cosmocol® range contains macrogol ‘3350’
1.7 Local preparations for anal and rectal disorders
Uniroid HC® ointment & suppositories Xyloproct® ointment
Anusol® cream, ointment & suppositories Anusol HC® ointment & suppositories These products are Pharmacy OTC items and should be purchased.
2: CARDIOVASCULAR SYSTEM
2.1 Positive inotropic drugs Digoxin tablets 62.5mcg, 125mcg & 250mcg
2.2.1 Thiazides and related diuretics
Indapamide tablets 2.5mg
NICE Clinical Guideline 127 Hypertension
2.2.2 Loop diuretics Furosemide tablets 20mg & 40mg
2.2.3 Potassium-sparing diuretics and aldosterone antagonists
Spironolactone tablets 25mg & 50mg
4
BNF Section Preparations Comments
2.4 Beta-adrenoceptor blocking drugs
Atenolol tablets 25mg, 50mg & 100mg Bisoprolol tablets 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg & 10mg Propranolol tablets 10mg & 40mg Propranolol modified release capsules 80mg & 160mg
Also used for migraine prophylaxis
2.5.4 Alpha-adrenoceptor blocking drugs
Doxazosin tablets 1mg, 2mg & 4mg NB Not modified release
2.5.5.1 Angiotensin-converting enzyme inhibitors
Lisinopril tablets 2.5mg, 5mg, 10mg & 20mg Perindopril erbumine tablets 2mg, 4mg & 8mg Ramipril capsules 1.25mg, 2.5mg, 5mg & 10mg
NB not arginine
2.5.5.2 Angiotensin-II receptor antagonists
Candesartan tablets 4mg, 8mg, 16mg & 32mg Losartan tablets 25mg, 50mg & 100mg
2.6.1 Nitrates
Glyceryl trinitrate pump/aerosol spray 400mcg, 180dose Chemydur® (Isosorbide mononitrate MR) tablets 60mg
2.6.2 Calcium-channel blockers Diltiazem longer acting formulations
Amlodipine tablets 5mg and 10mg Tildiem MR® tabs 60mg Viazem XL® capsules 120mg, 180mg, 240mg, 300mg & 360mg. Angitil SR® capsules 90mg, 120mg & 180mg
Three times a day dose Once daily dose Twice daily dose
2.6.3 Other anti-anginal dugs Nicorandil tablets 10mg & 20mg
2.8 Anticoagulants and protamine
Warfarin tablets 500mcg, 1mg, 3mg & 5mg
Refer to Cardiac Network Guidance
2.9 Antiplatelet drugs Aspirin dispersible tablets 75mg Clopidogrel tablets 75mg
5
BNF Section
Preparations Comments
2.11 Antifibrinolytic drugs and haemostatics
Tranexamic acid tablets 500mg
2.12 Lipid-regulating drugs Simvastatin tablets 10mg, 20mg & 40mg Atorvastatin tablets 10mg, 20mg, 40mg & 80mg Pravastatin tablets 10mg, 20mg & 40mg
3: RESPIRATORY SYSTEM
3.1.1.1 Selective beta2 agonists Short acting Salbutamol 100mcg/dose inhaler CFC free Longer acting Easyhaler formoterol 12mcg/dose
3.1.2 Antimuscarinic bronchodilators
Ipratropium bromide 20mcg/dose inhaler CFC free Tiotropium bromide 18mcg inhalation powder, hard capsule Tiotropium Respimat® 2.5 mcg inhalation solution
3.1.3 Theophylline Phyllocontin Continus® tablets 225mg
3.1.4 Compound bronchodilator preparations
Tiotropium / Olodaterol 2.5 mcg / 2.5 mcg inhalation solution (Spiolto Respimat®) Aclidinium / Formoterol (Duaklir Genuair®) 340 mcg /12 mcg inhalation powder
COPD in adults only
6
BNF Section Preparations Comments
3.2 Corticosteroids Compound preparations
Clenil Modulite® cfc-free aerosol inhaler beclometasone dipropionate (BDP) 50, 100, 200 & 250 mcg per dose Asthma Fostair® cfc free inhaler 100/6 and 200/6 (beclometasone dipropionate 100mcg or 200mcg /formoterol fumarate dihydrate 6mcg) Fostair Nexthaler® 100/6 and 200/6
(beclometasone dipropionate 100mcg or 200mcg / formoterol fumarate dihydrate 6mcg dry powder inhaler) DuoResp Spiromax®
(budesonide 160mcg/formoterol fumarate dihydrate 4.5mcg dry powder inhaler (equivalent to a metered dose of 200mcg budesonide and 6mcg formoterol fumarate dihydrate)) DuoResp Spiromax® budesonide 320mcg formoterol fumarate dihydrate 9mcg dry powder inhaler (equivalent to a metered dose of 400mcg budesonide and 12mcg formoterol fumarate dihydrate) Symbicort Turbohaler® budesonide 100mcg/formoterol fumarate dihydrate 6mcg
Symbicort Turbohaler® budesonide 200mcg/formoterol fumarate dihydrate 6mcg
Adult use. 18 years + NB Fostair® cfc-free inhaler has extra fine particles and has 5 months shelf life once dispensed (100mcg extra-fine beclometasone dipropionate is equivalent to 250mcg cfc-free beclometasone dipropionate) Adult use. 18 years + Use within 6 months of first opening the pouch Adult use. 18 years + Use within 6 months of first opening the foil wrap Adult use. 18 years + Use within 6 months of first opening the foil wrap Child 6-12 years Shelf life 2 years Child 12-17 years Shelf life 2 years
7
BNF Section Preparations Comments
Compound preparations
COPD Fostair® cfc-free inhaler 100/ 6 (beclometasone dipropionate 100mcg/ formoterol fumarate dihydrate 6mcg) Fostair Nexthaler® 100/ 6
(beclometasone dipropionate 100mcg/ formoterol fumarate dihydrate 6mcg dry powder inhaler) Symbicort turbohaler® budesonide 400 mcg/ formoterol fumarate dihydrate 12mcg DuoResp Spiromax® budesonide 160mcg/ formoterol fumarate dihydrate 4.5mcg dry powder inhaler (equivalent to a metered dose of 200mcg budesonide and 6mcg formoterol fumarate dihydrate) DuoResp Spiromax® budesonide 320mcg/ formoterol fumarate dihydrate 9mcg dry powder inhaler (equivalent to a metered dose of 400mcg budesonide and 12mcg formoterol fumarate dihydrate)
NB Fostair® cfc-free inhaler has extra fine particles and has 5 months shelf life when dispensed (100mcg extra-fine beclometasone dipropionate is equivalent to 250mcg cfc-free beclometasone dipropionate) Shelf life 2 years Use within 6 months of first opening the foil wrap Use within 6 months of first opening the foil wrap
3.3.2 Leukotriene receptor antagonists
Montelukast tablets 10mg Montelukast chewable tablets sugar free 4mg & 5mg
3.4 Antihistamines, hyposensitisation, and allergic emergencies
Cetirizine tablets 10mg Chlorphenamine tablets 4mg Loratadine tablets 10mg
4: CENTRAL NERVOUS SYSTEM
4.1 Hypnotics and anxiolytics Diazepam tablets 2mg & 5mg Zopiclone tablets 3.75mg & 7.5mg
short term use – up to 4 weeks
8
BNF Section Preparations Comments
4.2 Drugs used in psychoses and related disorders
Chlorpromazine tablets 25mg, 50mg & 100mg Haloperidol capsules 500mcg Haloperidol tablets 1.5mg & 5mg. Risperidone tablets 500mcg, 1mg, 2mg, 3mg & 4mg
Olanzapine and Quetiapine initiated by Secondary Care
4.3.1 Tricyclic and related antidepressant drugs
Amitriptyline tablets 10mg, 25mg & 50mg
4.3.3 Selective serotonin re-uptake inhibitors
Fluoxetine capsules 20mg Sertraline tablets 50mg & 100mg Citalopram tablets 10mg, 20mg & 40mg
4.3.4 Other antidepressant drugs
Venlafaxine tablets 37.5mg & 75mg Vensir® XL capsules 75mg & 150mg
Twice a day dose Once a day dose NB Regular BP monitoring required.
4.4 CNS stimulants & drugs used for attention deficit hyperactivity disorder
Initiated by Secondary Care
4.5 Drugs used in the treatment of obesity
Orlistat capsules 120mg
TA22 replaced by Clinical Guideline 43 Obesity - for appropriate use and monitoring
4.6 Drugs used in nausea and vertigo
Betahistine tablets 8mg & 16mg Domperidone tablets 10mg Prochlorperazine tablets 5mg and buccal tablets 3mg
4.7.1 Non-opioid analgesics and compound analgesic preparations
Paracetamol tablets 500mg Paracetamol sugar free suspension 120mg/5ml & 250mg/5ml Zapain® (co-codamol 30mg/500mg)
tablets/caplets ◪
◪ = BNF - less suitable for prescribing
9
BNF Section Preparations Comments
4.7.2 Opioid analgesics Codeine phosphate tablets 30mg Morphine sulphate oral solution 10mg in 5ml Zomorph® capsules 10mg, 30mg, 60mg, 100mg & 200mg Fencino® (fentanyl) patches 12, 25, 50, 75 & 100 mcg/hour Matrifen® (fentanyl) patches 12, 25, 50, 75 & 100 mcg/hour Tramadol capsules 50mg
4.7.4.1 Treatment of acute migraine
Naratriptan tablets 2.5mg Sumatriptan tablets 50mg & 100mg Zolmitriptan tablets 2.5mg Zolmitriptan orodispersible sugar free tablets 2.5mg
NB not 5mg strength
4.7.4.2 Prophylaxis of migraine
See propranolol 2.4
4.8 Antiepileptic drugs Carbamazepine tablets 100mg, 200mg & 400mg Gabapentin 100mg, 300mg & 400mg capsules Tegretol® prolonged release (carbamazepine modified release) tablets 200mg & 400mg
MHRA advise prescribe by brand (Tegretol®) Recommendations only apply to management of neuropathic pain. Epilepsy patients are managed in Secondary Care
4.9 Drugs used in parkinsonism and related disorders
Initiated by Secondary Care
4.10.2 Nicotine dependence
Smoking cessation products are the financial responsibility of Public Health if the patient is referred into the stop smoking service. NRT, bupropion and varenicline are equal first choices in smoking cessation
10
BNF Section
Preparations Comments
5: INFECTIONS Refer to Bedfordshire Community Antimicrobial Prescribing Guidelines
5.1.1.1 Benzylpenicillin and phenoxymethylpenicillin
Phenoxymethylpenicillin tablets 250mg Phenoxymethylpenicillin sugar free oral solution 125mg/5ml and 250mg/5ml
5.1.1.2 Penicillinase-resistant penicillins
Flucloxacillin capsules 250mg & 500mg Flucloxacillin oral solution 125mg/5ml & 250mg/5ml
5.1.1.3 Broad-spectrum penicillins
Amoxicillin capsules 250mg & 500mg Amoxicillin sugar free suspension 125mg/5ml & 250mg/5ml Co-amoxiclav tablets 250mg/125mg & 500mg/125mg
5.1.3 Tetracyclines Doxycycline capsules 50mg & 100mg Oxytetracycline tablets 250mg Lymecycline capsules 408mg
2nd line to oxytetracycline
5.1.5 Macrolides Clarithromycin tablets 250mg & 500mg Clarithromycin suspension 125mg/5ml and 250mg/5ml Erythromycin gastro resistant tablets 250mg Erythromycin ethylsuccinate sugar free suspension 125mg/5ml & 250mg/5ml
NB Not modified release
5.1.8 Sulphonamides and trimethoprim
Trimethoprim tablets 100mg & 200mg Trimethoprim sugar free suspension 50mg/5ml
11
BNF Section Preparations Comments
5.1.11 Metronidazole and tinidazole
Metronidazole tablets 200mg & 400mg
5.1.13 Urinary-tract infections
Nitrofurantoin tablets 50mg & 100mg Nitrofurantoin modified release capsules 100mg
5.2 Antifungal drugs Fluconazole capsules 150mg Terbinafine tablets 250mg
5.3 Antiviral drugs Aciclovir tablets 200mg, 400mg & 800mg
5.5 Anthelmintics Mebendazole suspension 100mg in 5ml Mebendazole chewable sugar free tablets 100mg
Licensed use in child over 2 years Unlicensed use in child under 2 years – see BNFc
6: ENDOCRINE SYSTEM
6.1.1 Insulins Insulin (all forms)
Prescribe by brand name
6.1.1.3 Hypodermic equipment
Mylife® Penfine Classic needles 4mm/32 gauge & 6mm/32 gauge GlucoRx® Finepoint pen needles 4mm/31 gauge, 5mm/31 gauge & 6mm/31 gauge
Listed under Appliances, Hypodermic Equipment in Part IXA of the Drug Tariff
6.1.2.1 Sulphonylureas Gliclazide tablets 80mg
NB not modified release
6.1.2.2 Biguanides Metformin tablets 500mg & 850mg
NB not modified release
6.1.6 Diagnostic and monitoring devices for diabetes mellitus
MyLife Pura® test strips TRUEresult® blood glucose test strips
6.2 Thyroid and antithyroid drugs
Carbimazole tablets 5mg & 20mg Levothyroxine sodium tablets 25mcg, 50mcg & 100mcg
6.3 Corticosteroids Prednisolone tablets 1mg & 5mg Prednisolone Dompe® 1mg/1ml oral solution
NB Not enteric coated
12
BNF Section Preparations Comments
6.4.1.1 Oestrogens and HRT Elleste-Duet® tablets 1mg & 2mg Elleste -Solo® tablets 1mg & 2mg Evorel® 25, 50, 75 & 100 patches Premique® low dose tablets PrempakC® tablets 0.625mg & 1.25mg
6.4.2 Male sex hormones and antagonists
Finasteride tablets 5mg
6.6 Drugs affecting bone metabolism
Alendronic acid 70mg tablets Risedronate tablets 35mg
Weekly dosage - Not licensed for use in men. Weekly dosage
7: OBSTETRICS, GYNAECOLOGY, AND URINARY-TRACT DISORDERS
7.2 Treatment of vaginal and vulval conditions
Clotrimazole pessaries 500mg Estriol cream 0.01% with applicator Estradiol (Vagifem®) pessaries 10mcg
Refer to Bedfordshire Community Antimicrobial Prescribing Guidelines In Preganancy 100mg at night x 6 nights
7.3.1 Combined hormonal contraceptives Emergency contraception
Low strength: Loestrin 20® tablets Sunya 20/75® tablets Standard strength: Microgynon 30® tablets Ovranette® tablets Lizinna® Tablets Levonorgestrel 1.5mg tablets
13
BNF Section Preparations
Preparations
7.3.2.1 Oral progestogen-only contraceptives
Cerelle® tablets Micronor® (norethisterone) tablets 350mcg
For women who cannot tolerate oestrogen containing contraceptives or in whom such preparations are contraindicated
7.3.2.2 Parenteral progestogen-only contraceptives
Medroxyprogesterone 150mg/1ml suspension for injection pre filled syringe
7.3.2.3 Intra-uterine progestogen-only device
Mirena® 20mcg/24hours intrauterine device
7.4.1 Drugs for urinary retention
Tamsulosin MR capsules 400mcg
NB not tablets
7.4.2 Drugs for urinary frequency, enuresis and incontinence
1st choice Oxybutynin tablets 2.5mg and 5mg 2nd choice Tolterodine tablets 1mg & 2mg Tolterodine modified release capsules 4mg Neditol XL® Solifenacin tablets 5mg & 10mg
3rd choice
7.4.5 Drugs for erectile dysfunction
Sildenafil tablets 25mg, 50mg & 100mg
8: MALIGNANT DISEASE & IMMUNOSUPPRESSION
8.2 Drugs affecting the immune response
Initiated by Secondary Care
8.3 Sex hormones and hormone antagonists in malignant disease
Initiated by Secondary Care
9: NUTRITION AND BLOOD
9.1 Anaemias and some other blood disorders
Ferrous fumarate tablets 210mg Folic acid tablets 5mg Hydroxocobalamin injection 1mg (1000mcg) in 1ml
14
BNF Section Preparations
Preparations
9.2 Fluids and electrolytes Dioralyte® sachets (all flavours) x 20
9.4 Enteral Nutrition
Food fortification is 1st line, choice should be dietitian lead
Ensure you have weight, BMI and MUST score before prescribing
9.5 Minerals See 9.6. for calcium with vitamin D
9.6 Vitamins Accrete D3® tablets TheiCal D3® tablets chewable Calfovit D3 ® sachets
1.0 - 1.2g Calcium + 800iu Vit D per day recommended for the prophylaxis of osteoporosis in elderly housebound patients in Bedfordshire
One tablet twice a day Vit D 10mcg (400units) & calcium 600mg One tablet once a day Vit D 22mcg (880units) & calcium 1000mg One sachet once a day Vit D 20mcg (800units) & calcium 1.2g
10: MUSCULOSKELETAL AND JOINT DISEASES
10.1.1 Non-steroidal anti-inflammatory drugs
Ibuprofen tablets 200mg, 400mg & 600mg tablets Naproxen tablets 250mg & 500mg Mefenamic acid tablets 500mg
For dysmenorrhoea
10.1.2.2 Local corticosteroid injections
Methylprednisolone 40mg with lidocaine 10mg/1ml injection 1ml vial Methylprednisolone 80mg with lidocaine 10mg/1ml injection 2ml vial
15
BNF Section Preparations Comments
10.1.3 Drugs that suppress the rheumatic disease process
Methotrexate tablets 2.5mg and s/c injections- see shared care guidance
Initiated by Secondary Care
10.1.4 Gout and cytotoxic-induced hyperuricaemia
Allopurinol tablets 100mg & 300mg Colchicine tablets 500 mcg
Prophylaxis Acute attack
10.2 Drugs used in neuromuscular disorders
Baclofen tablets 10mg
10.3 Drugs for the treatment of soft-tissue disorders and topical pain relief
Ibuprofen 5% gel 50g & 100g Fenbid®
11: EYE
11.3 Anti-infective eye preparations
Chloramphenicol eye drops 0.5% Chloramphenicol eye ointment 1%
Refer to Bedfordshire Community Antimicrobial Prescribing Guidelines
11.4 Corticosteroids and other anti-inflammatory preparations
Sodium cromoglicate eye drops 2%
11.8 Miscellaneous ophthalmic preparations
Clinitas carbomer eye Gel® 0.2% Hypromellose eye drops 0.3%
Tear-Lac® - if preservative free required
12: EAR, NOSE, AND OROPHARYNX
12.1 Drugs acting on the ear Refer to Bedfordshire Community Antimicrobial Prescribing Guidelines
12.2 Drugs acting on the nose 1st choice Beconase® (beclometasone) aqueous nasal spray 200 dose 2nd choice Fluticasone furoate (Avamys®) nasal spray 120dose Naseptin® cream 15g
16
BNF Section Preparations Comments
12.3 Drugs acting on the oropharynx
Benzydamine sugar free mouthwash 0.15% 300ml Nystan® (nystatin) suspension 100,000 units in 1ml
13: SKIN
13.2 Emollient and barrier preparations
Percentage of Paraffin in brackets:
Cetraben® emollient cream (23.7%) Zerobase® emollient cream (21%) Zerocream® cream (27%) Zeroguent®cream (15%) ZeroAQS® cream (21%) Zerodouble® gel (30%) Zeroderm® Ointment (70%) Zerolatum® emollient bath (60%)
Safety Alert Paraffin-based products are HIGHLY FLAMMABLE. These products and items with their residue ( clothes and/ or bed clothes) should NEVER be placed near an open flame, including lighted cigarettes and other smoking equipment
13.4 Topical corticosteroids Betamethasone valerate cream and ointment 0.025% (Betnovate-RD®) Betamethasone valerate cream & ointment 0.1% Betamethasone valerate 0.1% scalp application (Betnovate® ) Clobetasone butyrate cream and ointment 0.05% (Eumovate® ) Hydrocortisone cream and ointment 0.5% & 1% Combination products Hydrocortisone 1% + miconazole nitrate 2% cream (Daktacort® ) Betamethasone valerate 0.1% + fusidic acid 2% cream (Fucibet® ) Hydrocortisone acetate 1% + fusidic acid 2% cream
13.5 Preparations for eczema and psoriasis
Calcipotriol ointment 50mcg/g Calcipotriol scalp solution 50mcg/ml
17
13.6 Acne and rosacea Adapelene cream/ gel 0.1% Clindamycin aqueous lotion/ alcoholic solution 1% Co-cyprindiol tablets 2000mcg/35mcg Erythromycin 40mg/ml +Zinc acetate 12mg/ml lotion (Zineryt®)
BNF Section Preparations Comments
13.7 Preparations for warts and calluses
Salatac® gel These products are Pharmacy OTC items and should be purchased.
13.9 Shampoos and other preparations for scalp and hair conditions
Ketoconazole shampoo 2%
13.10 Anti-infective skin preparations
Aciclovir cream 5% Clotrimazole cream 1% Fusidic acid cream 2% Rozex® cream & gel (metronidazole 0.75%)
Refer to Bedfordshire Community Antimicrobial Prescribing Guidelines
15: ANAESTHESIA
15.2 Local anaesthesia Lidocaine injection 1% - 2ml, 5ml, 10ml & 20ml Lidocaine injection 2% - 2ml, 5ml & 20ml
18
The following NICE published Technology Appraisals are included within this formulary in accordance with the clinical criteria set out within each guidance and subject to the clinical judgement of the treating clinician. Not all of these will be appropriate for routine initiation, or continuation of, prescribing by a GP.
Ref Title Date Issued
TA10 Asthma (children under 5) - inhaler devices Aug 2000
TA38 Asthma (older children) - inhaler devices Mar 2002
TA77 Insomnia - newer hypnotic drugs Apr 2004
TA81 Atopic dermatitis (eczema) - topical steroids Aug 2004
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus Aug 2004
TA98 Methylphenidate, atomoxetine & dexamfetamine for ADHD in children & adolescents Mar 2006
TA114 Drug misuse - methadone & buprenorphine Jan 2007
TA115 Drug misuse - naltrexone Jan 2007
TA123 Smoking cessation - varenicline July 2007
TA131 Asthma (in children) - corticosteroids Nov 2007
TA134 Psoriasis - infliximab Jan 2008
TA138 Asthma (in adults) - corticosteroids Mar 2008
TA146 Psoriasis - adalimumab Jun 2008
TA151 Diabetes - insulin pump therapy July 2008
TA157 Venous thromboembolism - dabigatran Sep 2008
TA158 Influenza (prophylaxis) - amantadine, oseltamivir & zanamivir Sep 2008
TA160 Osteoporosis - primary prevention Jan 2011
TA161 Osteoporosis - secondary prevention including strontium ranelate Jan 2011
TA163 Ulcerative colitis (acute exacerbations) - infliximab Dec 2008
TA168 Influenza - zanamivir, amantadine and oseltamivir Feb 2009
TA170 Venous thromboembolism - rivaroxaban Apr 2009
TA177 Treatment of severe chronic hand eczema - alitretinoin Aug 2009
TA180 Psoriasis - ustekinumab Sep 2009
TA187 Infliximab and adalimumab for the treatment of Crohn's disease May 2010
TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor Aug 2010
TA197 Atrial fibrillation - dronedarone (re-issued) Dec 2012
TA199 Psoriatic arthritis - etanercept, infliximab & adalimumab Aug 2010
TA204 Osteoporotic fractures - denosumab Oct 2010
TA210 Vascular disease - clopidogrel and dipyridamole Dec 2010
TA211 Constipation (women) - prucalopride Dec 2010
TA213 Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years Jan 2011
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine Mar 2011
TA220 Psoriatic arthritis - golimumab Apr 2011
TA221 Romiplostim for chronic immune idiopathic thrombocytopenic purpura (ITP) Apr 2011
TA223 Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate
May 2011
19
Ref Title Date Issued
TA236 Acute coronary syndromes - ticagrelor Oct 2011
TA238 Arthritis (juvenile idiopathic, systemic) - tocilizumab Dec 2011
TA245 Venous thromboembolism - apixaban (hip and knee surgery) Jan 2012
TA248 Diabetes (type 2) - exenatide (prolonged release) Feb 2012
TA249 Atrial fibrillation - dabigatran etexilate Mar 2012
TA256 Atrial fibrillation (stroke prevention) - rivaroxaban May 2012
TA261 Venous thromboembolism (treatment & long term secondary prevention) - rivaroxaban July 2012
TA265 Bone metastases from solid tumours - denosumab Oct 2012
TA266 Cystic fibrosis - mannitol dry powder for inhalation Nov 2012
TA267 Chronic heart failure - ivabradine Nov 2012
TA274 Macular oedema (diabetic) - ranibizumab Feb 2013
TA275 Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban Feb 2013
TA276 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin Mar 2013
TA283 Macular oedema (retinal vein occlusion) - ranibizumab May 2013
TA287 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban Jun 2013
TA288 Type 2 diabetes - Dapagliflozin combination therapy Jun 2013
TA290 Overactive bladder - mirabegron Jun 2013
TA292 Bipolar disorder manic episodes (adolescents 13yrs and above) - aripiprazole July 2013
TA293 Thrombocytopenic purpura - eltrombopag July 2013
TA294 Macular degeneration (wet age-related) - aflibercept July 2013
TA297 Vitreomacular traction - ocriplasmin Oct 2013
TA298 Choroidal neovascularisation (pathological myopia) - ranibizumab Nov 2013
TA301 Diabetic macular oedema - fluocinolone acetonide intravitreal implant Nov 2013
TA305 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection Feb 2014
TA315 Canagliflozin in combination therapy for treating type 2 diabetes Jun 2014
TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)
July 2014
TA318 Lubiprostone for treating chronic idiopathic constipation July 2014
TA323 Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142)
Nov 2014
TA325 Nalmefene for reducing alcohol consumption in people with alcohol dependence Nov 2014
TA327 Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dec 2014
TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Feb 2015
TA335 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Mar 2015
TA336 Empagliflozin in combination therapy for treating type 2 diabetes Mar 2015
TA337 Rifaximin for preventing episodes of overt hepatic encephalopathy Mar 2015
20
Ref Title Date Issued
TA340 Ustekinumab for treating active psoriatic arthritis Jun 2015
TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis and / or pulmonary embolism
Jun 2015
TA342 Vedolizumab for treating moderately to severely active ulcerative colitis Jun 2015
TA345 Naloxegol for treating opioid-induced constipation July 2015
TA346 Aflibercept for treating diabetic macular oedema July 2015
TA349 Dexamethasone intravitreal implant for treating diabetic macular oedema July 2015
TA350 Secukinumab for treating moderate to severe plaque psoriasis July 2015
TA351 Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminated appraisal)
July 2015
TA352 Vedolizumab for moderately to severely active Crohn’s disease after prior therapy. (Hospital Trust)
Aug 2015
TA354 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Aug 2015
TA355 Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Sep 2015
TA358 Tolvaptan for treating autosomal dominant polycystic kidney disease. Oct 2015
TA369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Dec 2015
TA372 Apremilast for treating active psoriatic arthritis Dec 2015
TA375 Certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Jan 2016
TA383 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Feb 2016
TA385 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Feb 2016
TA388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction Apr 2016